Additionally, the 36-month beta value for NVNO is 1.39. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NVNO is 17.37M and currently, short sellers hold a 2.49% ratio of that float. The average trading volume of NVNO on February 21, 2025 was 143.62K shares.
NVNO) stock’s latest price update
The stock price of enVVeno Medical Corporation (NASDAQ: NVNO) has jumped by 6.41 compared to previous close of 3.59. Despite this, the company has seen a gain of 15.06% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-19 that On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
NVNO’s Market Performance
NVNO’s stock has risen by 15.06% in the past week, with a monthly rise of 9.46% and a quarterly rise of 16.46%. The volatility ratio for the week is 9.80% while the volatility levels for the last 30 days are 7.60% for enVVeno Medical Corporation The simple moving average for the past 20 days is 15.22% for NVNO’s stock, with a -9.23% simple moving average for the past 200 days.
NVNO Trading at 20.84% from the 50-Day Moving Average
After a stumble in the market that brought NVNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.19% of loss for the given period.
Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 9.80%, as shares surge +8.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.07% upper at present.
During the last 5 trading sessions, NVNO rose by +15.06%, which changed the moving average for the period of 200-days by -24.51% in comparison to the 20-day moving average, which settled at $3.32. In addition, enVVeno Medical Corporation saw 26.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVNO starting from Duhay Francis, who purchase 81,433 shares at the price of $3.07 back on Dec 31 ’24. After this action, Duhay Francis now owns 102,344 shares of enVVeno Medical Corporation, valued at $249,999 using the latest closing price.
Gray Robert, the Director of enVVeno Medical Corporation, purchase 3,500 shares at $2.94 during a trade that took place back on Dec 31 ’24, which means that Gray Robert is holding 11,155 shares at $10,290 based on the most recent closing price.
Stock Fundamentals for NVNO
Current profitability levels for the company are sitting at:
- -28.4 for the present operating margin
- 0.34 for the gross margin
The net margin for enVVeno Medical Corporation stands at -25.78. The total capital return value is set at -0.49. Equity return is now at value -58.76, with -54.12 for asset returns.
Based on enVVeno Medical Corporation (NVNO), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -14.55. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -57.79.
Currently, EBITDA for the company is -25.02 million with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of 60.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.01.
Conclusion
In conclusion, enVVeno Medical Corporation (NVNO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
